Activity of angiotensin converting enzyme in blood serum of patients with stable effort angina

Kardiologiya

Volumn 46, Issue 4, 2006, Pages 10-12

  Ganelina, I E ^a   Nikolaeva, E P ^a   Skvertchinskaya, E A ^a  

^a SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

Author keywords

Angiotensin converting enzyme; Ischemic heart disease; Stable effort angina

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; ENZYMOLOGY; EXERCISE; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANGINA PECTORIS; CORONARY ANGIOGRAPHY; EXERTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 33745393888     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Schtrmund A., Lerman J. O., Ritman E. L. et al. Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. Mayo Clin Proc 1999;74:503-513.
2. Schmidt-Ott K.M., Kagiyamu M., Phillips I. The multiple actions of angiotensin II in atherosclerosis. Regulat Pept 2000;93:65-77.
3. Zhang H., Schmesser A., Plotz K. et al. Angiotensin II induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADpH-OXIDASE. Cardiovasc Res 1999;44:215-222.
4. Linz W., Wohlart P., Bernard A. et al. Interactions among ACE, kinins and NO. Cardiovasc Res 1999;43:549-561.
5. Griffin S.A., Brown W.C.B., MacPherson F. et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991;17:626-635.
6. Hemidez-Presa B.S., Bustos C., Ortego B.S. et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor kB activation monocyte chemoattractant protein-I expression and macrophage infiltration in rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-1541.
7. Grafe M., Auch-Schwelk W., Zakrzewiez A. et al. Angiotensin II - induced leukocyte adhesion of human coronary endothelial cells in mediated by E-selection. Cardiovasc Res 1997;81:804-811.
8. Takagishi T., Murahashi N., Azagami S. et al. Effect of angiotensin II and thromboxane A2 on the production of matrix metalloproteinase by human aortic smooth myscle cells. Biochem Mol Biol Int 1995;35:265-273.
9. Vaughan D.E. The rennin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79:5A:12-16.
10. Diel F., Pratt R.E., Berry G.J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1976;94:2756-2767.
11. Campeau L. Grading of angina pectoris. Circulation 1976;54:522-523.
12. Hermidez-Presa M., Bustos C., Ortego M. et al. Angiotensin converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-1541.
13. Vanhoutte P.M., Auch-Schwelk W., Biondi M.L. et al. Why are converting enzyme inhibitors vasodilatators? Br J Pharmacol 1989;54:298-304.
14. Sudhir K., MacGregor I. S., Gupta M. Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: intravascular two-dimensional and Doppler ultrasound studies. Circulation 1993;87:931-938.
15. Chobanian A.V., Haudenschild C.C., Nickerson C. et al. Anti-atherogenic effect of captoril in the Westanabe heritable hyperlipedemic rabbits. Hypertension 1990;15:327-331.
16. Chobanian A.V., Haudenschild C.C., Nickerson C. et al. Trandolapril inhibits atherosclerosis in the Westanabe heritable hyperlipedemic rabbits. Hypertension 1992;20:473-477.
17. Mancini G.B., Henry G.C., Macaya C. et al. Trial-Reversing Endothelial Dysfunction Study (TREND). Circulation 1996;94:257-265.
18. Murohara T., Tayama S., Tabuchli T. et al. Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment. Am J Cardiol 1996;77:1159-1163.
19. Fox K.M., Henderson J.K., Bertrand M.E. et al. The Europian trial on reduction of cardial events with prendopril in coronary artery disease (EUROPA). Eur Heart J 1998;29:Suppl 5:152-155.
20. Wright R.A., Flapan A.D., Albert K.G.M.M. etal. Effects of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
21. Van den Heuvel A.F., Van Giest W.H., Van Veldhusen D.J. et al. Captopril and Thrombolysis Study (CATS). Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. J Am Coll Cardiol 1994;30:400-405.
22. Ambrosin E., Borghi C., Magnani B. The effect of the angiotensin- converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction: the Survival of myocardial infarct on Long-Term Evaluation (SMILE) Study. N Engl J Med 1995;332:80-83.
23. Kober L., Torp-Pederson C., Carlson J. et al. The effect on the angiotensin-converting enzyme inhibitor zofenopril for the Trandolapril Cardial Evaluation (TRACE) Study Group. A clinical trial of the angiotensinconverting- enzyme inhibitor trandonipril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-1767.